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Background: Oxidative stress biomarkers such as superoxide dismutase (CuZnSOD), catalase (CAT) and
malondialdehyde (MDA) play an important role in the pathogenesis or progression of numerous diseases. Data
regarding the biological variation and analytical quality specifications (imprecision, bias and total error) for judging
the acceptability of method performance for oxidative stress biomarkers in urine are conspicuously lacking in the
literature. Such data are important in setting analytical quality specifications, assessing the utility of population
reference intervals (index of individuality) and assessing the significance of changes in serial results from an
individual (reference change value; RCV).
Materials and methods: 20 patients with type 2 diabetes mellitus (T2DM), 20 patients with diabetic nephropathy
(DN) and 14 healthy individuals as control were involved in this study. Timed first morning urine samples were
taken from patients and healthy groups on the zero, 1st, 3rd, 5th, 7th, 15th and 30th days. Index of individuality and
reference change value were calculated from within-subject and between-subject variations. Methods of oxidative stress
biomarkers in human blood were adopted in human urine and markers were measured as spectrophotometrically. Also,
analytical quality specifications for evaluation of the method performance were established for oxidative stress biomarkers
in urine.
Results: Within-subject variations of oxidative stress biomarkers were significantly higher in patients with DN and T2DM
compared to healthy subjects. MDA showed low individuality, and within-subject variances of MDA were larger than
between-subject variances in all groups. However, CAT and CuZnSOD showed strong individuality, but within-subject
variances of them were smaller than between-subject variances in all groups. RCVs of all analytes in diabetic patients were
relatively higher, because of high within-subject variation, resulting in a higher RCV. Also, the described methodology
achieves these goals, with analytical CVs of < 3.5% for all analytes. Goals for bias and total error were 6.0-7.9% and
12.5-23.3%, respectively.
Conclusions: RCVs concept for predicting the clinical status in diabetic patients represents an optimization of laboratory
reporting and could be a valuable tool for clinical decision. Furthermore, for oxidative stress biomarkers’ measurements in
urine, the desirable imprecision goals based on biological variation are obtainable by current methodologies.
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Oxidative stress is an imbalance between reactive oxygen
species (ROS) and protective radical scavenging antioxi-
dants resulting from either an overproduction of ROS or a
deficit in antioxidant protection [1]. Oxidative stress bio-
markers such as catalase (CAT), superoxide dismutase
(CuZnSOD) and malondialdehyde (MDA) are increasingly
being evaluated in experimental, clinical and epidemio-
logical studies and have been implicated in the pathogen-
esis of numerous diseases including atherosclerosis,
cancer, diabetes, respiratory disease and others [2].
The biological component is characterized by the bio-
logical within-subject variation during the stable phase of a
disease. Many authors have studied within-individual vari-
ation in the concentrations of biochemical analytes in
serum, plasma and urine from apparently healthy individ-
uals [3-5]. However, one cannot apply data from healthy in-
dividuals because the disease itself may influence the
magnitude of variation. Using biological variation to derive
analytical performance criteria begins with determining
how much natural variation is expected for a test result.
The concentration of measurand in individuals varies
around their baseline or homeostatic set-point. The total
variation observed is composed of preanalytical variation,
analytical variation (imprecision and bias), and inherent
within-person biological variation. In a laboratory setting,
we can control preanalytical and analytical variability, leav-
ing the biological component as the only true variable. If
preanalytical error related to phlebotomy, transport, hand-
ling, and storage of samples is minimized, and the analytical
variation is considerably less than the biological variability,
serial testing can be used to determine whether a patient
has improved [6,7]. Determining the effect of analytical vari-
ation relative to biological variation is a straightforward way
to develop desirable performance criteria of an assay [8,9].
Measuring the degree of oxidative stress is not in wide
clinical use, since no standardized method has been ac-
cepted for measuring the oxidative stress status and lipid
peroxidation in humans. These analyte measurements are
important and the need to investigate relationships be-
tween clinical outcome and laboratory tests requires reli-
able reference values. Some information is available on the
biological variations of oxidative stress biomarkers. Browne
et al. reported that biologic within-subject variations of
oxidative stress biomarkers in erythrocyte didn’t change
during menstrual cycle [10]. Diaz et al. showed that oxida-
tive stress biomarkers in human plasma can be adapted for
screening patients who may be subject to oxidative stress,
and can be used for the routine monitoring of lipid peroxi-
dation in human disorders [11]. We previously showed the
levels of oxidative stress biomarkers in urines of patients
with urinary tract infection and diabetic patients [12,13].
However, to the best of our knowledge, none of the previ-
ous researches investigated the biological variations ofantioxidant enzymes (CAT, CuZnSOD) and MDA in
urines of healthy individuals as well as in urines of patients
with diabetic nephropathy (DN) and type 2 diabetes melli-
tus (T2DM). Therefore, 1) to assess the components of
variation of CAT, CuZnSOD and MDA analytes signifi-
cantly affected by a pathological process, we investigated
the biological variation of CAT, CuZnSOD and MDA ana-
lytes in patients with DN and T2DM. 2) we have defined
the contributions to the overall variance of analytical,
within-, between-subject variance for each of oxidative
stress biomarkers in the assessment of DN and T2DM.
Furthermore, the data were used to calculate the reference
change value (RCV) required for the assessment of the sig-
nificance of changes in serial results from an individual
and to define analytical quality specifications for evaluation
of method performance such as imprecision (I), bias (B)
and total error (TE).
Materials and methods
Subjects
All subjects were volunteers who were informed about the
objective of the study before- hand. During the course of
the study no illness or injury was observed in the healthy
individuals and no additional illness was observed in
T2DM and DN patients. American Diabetes Association
criteria were used for diagnosis of T2DM [14] and the
Kidney Disease Outcomes Quality Initiative criteria were
used for diagnosis of DN [15]. During the study, treatment
of T2DM or DN patients was not changed, the disease
process being considered stable. T2DM and DN patients
underwent either a fundoscopic examination or fluoroan-
giographic study for diagnosis of retinopathy. Patients with
drug induced nephrotoxic damage or secondary causes of
renal insufficiency such as obstructive renal disease, renal
stone disease, and acute urinary tract infection were ex-
cluded. The patients who were known to have a familial
disease such as autosomal dominant polycystic kidney dis-
ease or Alport disease were not included in the study.
Healthy reference group
This group consisted 8 females, ages 49 to 59 years
(mean 53.0 years), and 7 males, ages 49 to 55 years
(mean 52.4 years). All were apparently healthy and none
was taking any drugs, including oral contraceptives.
T2DM reference group
There were 9 females, aged 50 to 55 years (mean
52.2 years) and 11 males, aged 50 to 62 years (mean
55.0 years) in this group.
DN reference group
Ten females, aged 45.0 to 61.0 years (mean 53.0 years)
and 10 males, aged 49 to 60 years (mean 54.4 years)
were included in this group.
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were listed in Table 1. Approval from the Ethics Com-
mittee of Kahramanmaras Sutcu Imam University Me-
dical Faculty was taken in accordance with the principles
of Declaration of Helsinki and informed consent was ob-
tained from the cases.
Analytical techniques
Blood samples
The blood samples were taken from each individual on
the zero day of our study. The analytical methods for rou-
tine biochemical analysis were standard for the medical la-
boratories. In brief, the basic principles and instruments
involved were as follows. Measurements of total protein
(biuret reaction), fasting blood glucose (FBG) (hexokinase/
glucose-6-phosphate dehydrogenase) albumin (bromcresol
green), urea (urease/glutamate dehydrogenase), creatinine
(Jaffe reaction) were performed by Siemens Advia 1800
analyzer (Germany). Also, glycosylated haemoglobin
(HbA1c) (HPLC method) was determined by Adams
HA-8160 analyzer (Japan).
Urine samples
The 55 urine samples which were collected in a particular
time interval were included in the study. The urine sam-
ples of subjects were collected into 75-mL sterile con-
tainers (Kayline Plastics, The Barton, South Australia,
5031). To control the urine concentration, data were nor-
malized to urine creatinine concentration. Urinary creatin-
ine was measured in spot urine samples by Dade BehringTable 1 Comparisons of demographic and laboratory data am
Variables T2DM
Age (years)
Female 52.20 ± 2.16
Male 55.00 ± 4.47
BMI (kg/m2) 23.20 ± 1.30






GFR (mL/min/1.73 m2) 100.29 ± 13.59*
HbA1c (mmol/mol) 63.5 ± 9.5*
FBG (mmol/L) 8.8 ± 0.4*
Serum creatinine (micromol/L)
Female 123.6 ± 6.15
Male 137.7 ± 9.15**
*Significant differences in patients with T2DM and DN compared to healthy individ
**Significant differences in creatinine levels between male and female subjects in aDimension RXL autoanalyzer (Germany). Then, all urine
specimens were stored frozen at −70°C until testing at the
end of the collection period.
To minimize interbatch analytical variation, all sam-
ples from any volunteer were analysed in two batches
for CAT, CuZnSOD and MDA; therefore, 30 different
batches were run over a period of 30 days. The same lot
of combined standard and quality control (QC) material
were used throughout, and analyses were performed by
a single analyst. Aliquots of a single urine pool, stored at
−70°C, were used as the in-house QC material, and ana-
lysed in duplicate in each batch.
Determination of oxidative stress biomarkers in urine
Method of oxidative stress biomarkers in human blood
were adopted in human urine (12, 13). At the start of
our study, all urine samples were diluted with 1:50
serum physiologic (0.9% NaCI) for oxidative stress bio-
markers analysis.
Superoxide dismutase assay CuZnSOD activity in the
urine samples was measured by the method of Fridovich
[16]. The method for CuZnSOD activity employed xanthine
and xanthine oxidase to generate superoxide radicals which
react with p-iodonitrotetrazolium violet (INT) to form
a red formazan dye which was measured at 505 nm.
Assay medium consisted 0.01 M phosphate buffer, 3-
cyclohexylamino-1-propanesulfonic acid (CAPS), buffer
solution (50 mM CAPS, 0.94 mM EDTA, saturated
NaOH) with a pH of 10.2, solution of substrate (0.05 mMong T2DM, DN and healthy individuals
DN Healthy individuals
53.00 ± 6.78 53.00 ± 3.80
54.40 ± 3.91 52.40 ± 2.40
22.98 ± 2.32 22.40 ± 1.51






43.68 ± 10.29* 116.80 ± 12.31*
65.3 ± 6.0* 31.8 ± 5.6
7.0 ± 0.5* 4.9 ± 0.9
145.5 ± 8.1 77.4 ± 7.4
163.6 ± 24.3** 105.1 ± 6.9**
uals (p < 0.05).
ll groups (p < 0.05).
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CuZnSOD activity was expressed as U/L.
Catalase assay CAT activity in the urine samples was
measured by the method of Beutler [17]. CAT activities
were determined by measuring the decrease in hydrogen
peroxide concentration at 230 nm. Assay medium con-
sisted 1 M Tris–HCl, 5 mM Na2EDTA buffer solution
(pH 8.0), 1 M phosphate buffer solution (pH 7.0), and
10 mM H2O2. CAT activity was expressed as U/L.
Malondialdehyde assay MDA concentration, as an indi-
cator of lipid peroxidation, in the urine samples were de-
termined according to procedure of Ohkawa [18]. The
reaction mixture contained 0.1 mL sample, 0.2 mL of 8.1%
sodium dodecyl sulfate, 1.5 mL of 20% acetic acid, and
1.5 mL of 0.8% aqueous solution of thiobarbituric acid.
The mixture pH was adjusted to 3.5 and the volume was
finally made up to 4.0 mL with distilled water and 5.0 mL
of the mixture of n-butanol and pyridine (15:1, v/v) was
added. The mixture was shaken vigorously. After centrifu-
gation at 4000 rpm for 10 minutes, the absorbance of the
organic layer was measured at 532 nm. MDA concentra-
tion was expressed as nmol/mL.
Glomerular filtration rate (GFR) assay
The GFR is considered most suitable for quantifying
renal function. Practical limitations exist in measuring
GFR directly, especially in acutely ill patients. Several re-
liable equations incorporating clinical variables to esti-
mate the GFR are available; we used the Modification of
Diet in Renal Disease equation [19].
Statistical analysis
Seven urine samples were taken from each individual on
the zero, 1st, 3rd, 5th, 7th, 15th and 30th days. Variation
analyses were performed on natural logarithmic trans-
formed data after exclusion of outliers using Cochran
and Reed tests. The Cochran test did not highlight any
outliers among duplicate measurements; however, it did
identify results for seven samples from different subjects
(five T2DM, all analytes; and two healthy individuals,
MDA) as outliers among within-subject variances. The
Reed test identified MDA for one healthy individual as
an outlier. After exclusion of outliers, biological variation
data were estimated according to the method published
by Fraser et al. [20-24]. Analytical variance (SDA
2) was
calculated from the differences between the duplicates
according to the formula:
SDA
2 ¼ Σd2=2n
where d is the difference between duplicates and n is the
number of duplicates. The SDA
2 is expressed as relativeSDA to the first sample concentration, analytical coeffi-
cient of variation (CVA). For each analyte, one-way ana-
lysis of variance was used to divide the total variance
into between-subject (SDG
2) variance and total within-
subject variance (SDTI
2). Since SDTI
2 includes both bio-
logical and analytical components, the within-subject
variance (SDI
2) was obtained by subtraction using the
formula:
SI
2 ¼ STI − SA2
Within-subject and between-subject biological varia-
tions were expressed as the coefficient of variation by
the use of homeostatic mean of each individual, within-
subject coefficient of variation (CVI) and the overall
mean, between-subject coefficient of variation (CVG), re-
spectively. Index of individuality (II) was calculated as
CVI/CVG whereby a low value (<0.60: high individuality)
indicated a low usefulness of population-based reference
intervals, whereas a high value (>1.40: low individuality)
indicated a high usefulness of population-based refer-
ence intervals, particularly when an unusual result was
repeated for verification.
RCV, which is the difference required for two serial
measurements of the oxidative stress biomarkers to have
significantly changed at p < 0.05, was calculated as in [25]:
RCV ¼ 21=2x Z x CVA2 þ CV I2
 1=2 ¼ 2:77CVTI
Z-score was accepted as 1.96 (95% probability, bidirec-
tional z-score).
Biological variation data for oxidative stress biomarkers
were used to estimate the desirable quality specifications
for I, B and TE, using the following formulas [26].
I ¼ 0:5CV I
B ¼ 0:25 CVI2 þ CVG2
 1=2
TE ¼ 1:65 0:25CV Ið Þ þ 0:25 CV I2 þ CVG2
 1=2
Differences of the mean biological within-subject vari-
ances between the reference groups (DN/healthy,
T2DM/healthy, DN/T2DM, as paired comparison) were
checked by the F test. Linear regression analysis was
used to check for significant trends in values for CAT,
CuZnSOD and MDA and to investigate the time de-
pendence of the within-subject variations. Group com-
parisons (like male versus female, DN/T2DM, DN/
healthy, T2DM/healthy, etc.) were performed using the
Mann–Whitney U test. A p value <0.05 was considered
to be statistically significant.
Results
The demographic characteristics and results of some
biochemical analytes of the reference groups were listed
Table 3 Biological variation components in patients with





CAT 18.09 32.07 0.56 50.10
CuZnSOD 14.45 27.03 0.53 40.02
MDA 31.39 17.28 1.81 86.95
DN patients
CAT 15.14 29.67 0.51 41.93
CuZnSOD 8.61 24.02 0.35 23.84
MDA 25.40 16.25 1.56 70.35
Healthy Individuals
CAT 9.08 23.48 0.38 27.92
CuZnSOD 5.60 31.08 0.18 15.51
MDA 21.00 11.96 1.50 49.86
While the results of CAT and CuZnSOD activities were expressed as U/L, MDA
concentration was expressed as nmol/mL.
aCVTI, within-subject coefficient of variation;
bCVG, between-subject coefficient
of variation; cII, index of individuality; dRCV, reference change value (with
95% confidence).
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similar in all groups. HbA1c and FBG concentrations in
patients with DN and T2DM were higher than healthy
individuals. Serum creatinine concentrations in male
were higher than female, and there was significant differ-
ence according to gender (p < 0.05). However, there was
no significant difference according to age (p > 0.05). Esti-
mated GFR in DN was seen at stage 3 of kidney damage.
Of the 1155 data points, 8 were classified as outliers.
The number of remaining data points for each analyte is
shown in Table 2. A uniform distribution of these out-
liers was observed among samples and subjects. The ac-
tivities of CuZnSOD and CAT decreased, and MDA
concentrations increased in patients with DN compared
to healthy individuals (p < 0.05). However, all of them ex-
cept CuZnSOD increased in patients with T2DM com-
pared to healthy individuals (p < 0.05).
Table 3 shows that the means of total within-subject
variations in patients with DN and T2DM were signifi-
cantly higher than healthy individuals (p < 0.05). Also,
biological within-subject variances of MDA were larger
than between-subject variances in all reference groups.
However, within-subject variances of CAT and CuZn-
SOD were smaller than between-subject variances in all
reference groups. While MDA showed low individuality
(II > 1.40), CAT and CuZnSOD showed strong individu-
ality (II < 0.60). The RCV values of CAT, CuZnSOD and
MDA in patients with T2DM and DN were markedly
higher than healthy individuals (p < 0.05).
Data regarding the imprecision of the method are pre-
sented in Table 4. The imprecision of our laboratory
method for measuring CAT, CuZnSOD and MDA in urine
was less than the desirable imprecision goals. For eachTable 2 The levels of oxidative stress biomarkers in all of
the reference groups
Mean Median Reference interval
T2DM group
CAT 0.63* 0.62 0.25-0.95
CuZnSOD 5.08* 4.99 3.00-7.34
MDA 3.87* 3.92 1.00-6.98
DN group
CAT 0.24* 0.23 0.12-0.37
CuZnSOD 3.68* 3.60 1.87-6.00
MDA 4.56* 5.01 1.09-7.00
Healthy Individuals
CAT 0.36 0.35 0.15-0.73
CuZnSOD 5.39 5.08 2.77-10.70
MDA 0.59 0.54 0.10-1.53
While the results of CAT and CuZnSOD activities were expressed as U/L, MDA
concentration was expressed as nmol/mL.
*Significant differences in patients with T2DM and DN compared to healthy
individuals (p < 0.05).analyte, the imprecision of the laboratory method and the
desirable specifications for imprecision (I), bias (B), and
total error (TE) derived from the biological variation data
are presented in Table 5. The described methodology
achieves these goals, with analytical CVs of < 3.5% for all
analytes. Goals for bias and total error were 6.0-7.9% and
12.5-23.3%, respectively.
The regression analysis showed no trends for the
changes in the activities of CAT and CuZnSOD, and MDA
concentration during 30 days in all reference groups.
Discussion
To our knowledge, this is the first study carrying out the
determination and application of data on biological vari-
ations of oxidative stress biomarkers in urines of patients
with T2DM and DN as well as healthy individuals. Lim-
ited studies have been conducted to address these meth-
odological issues and there is still controversy over
which biomarkers to use. It has been suggested thatTable 4 Precision (CV) of oxidative stress biomarkers’
measurements in urine using the described
spectrophotometric method
*Within batch **Between batch
Analyte Mean CV (%) Mean CV (%)
CAT (U/L) 0.31 1.6 22.20 3.1
CuZnSOD (U/L) 5.19 2.3 4.99 3.3
MDA (nmol/mL) 0.57 1.9 0.49 3.2
*Within batch imprecision was calculated by analysing a pooled urine sample
10 times on the same day. **Between batch imprecision data were obtained
from the in house QC material analysed in duplicate in 30 batches over a
period of 30 days, as described in the statistical analysis section.
Table 5 Laboratory method imprecision (CVA) and
desirable specifications for imprecision (I), bias (B) and
total error (TE) derived from biological variation
Desirable specifications Method imprecision
Analytes I (%) B (%) TE (%) CVA (%)
CAT 4.5 6.3 13.7 3.1
CuZnSOD 2.8 7.9 12.5 3.2
MDA 10.5 6.0 23.3 3.3
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search purposes until more sensitive and specific assays
are developed [27]. In this study we generated data of
biological variations for oxidative stress biomarkers that
are commonly measured in the laboratory when asses-
sing oxidative stress.
In measuring the within-subject variation in chronic
diseases one must define a time interval during which
the process of the disease is practically stable and the
consecutively measured individual values are independ-
ent of each other. Under these conditions, the measured
within-subject variation can be used to derive decision-
making criteria in long-term monitoring of the disease.
During 30-days-intervals in this study the process of DN
and T2DM could be regarded as stable. In our study, the
biological within-subject variation of CuZnSOD, CAT and
MDA analytes was statistically higher in the DN and
T2DM subjects than in healthy individuals. The high glu-
cose concentration in bothT2DM and DN patients, as well
as renal impairment in DN patients may be the cause of
high within-subject variations. In spite of the fact that
these individuals have a higher within-subject variation, we
suggest that, for these the mean values should be used in
deriving decision criteria. However, we found no signifi-
cant difference in the within-subject variation of CAT and
CuZnSOD in all groups, so these antioxidant enzymes can
be used in deriving criteria for decision making. Further-
more, our results indicated that between-subject variations
for CAT and CuZnSOD in all groups were generally larger
than within-subject variation. We thought that CAT and
CuZnSOD displaying small within-subject variation also
allow more precise knowledge of the homeostatic set point
and leave less margin for ambiguity in recognizing the pa-
tient’s status. However, our estimates of within-subject var-
iations for MDA indicating that there were significant
differences may be attributed day-to-day biological vari-
ation in lipid peroxidation. Also, we found that the mean
total between-subject variances of MDA were smaller than
within-subject variances in all groups, probably because of
the lack of homogeneity in the within-subject variation
and perhaps due to problems of stability. The lack of
homogeneity in the data of MDA analyte may cause erro-
neous calculations of biological variation and false inter-
pretations of results, as such calculations involve ananalysis of means and may incorporate individuals with
within-subject variation values much larger than between-
subject variations. The II has been used by many to
investigate the utility of conventional population-based
reference values. For a high index of individuality, >1.4, it
has been reported that reference intervals will be more
useful than for a low index, <0.6. For quantities with very
low indices, a repeat test result will be close to the first
and will provide no new information, whereas for quan-
tities with high indices, a repeat test will decrease the
number of true and false positivity [28,29]. In our study,
the calculated indices of individuality for CAT and CuZn-
SOD in T2DM, DN and healthy subjects in all groups
were less than 0.6 which showed conventional reference
values to be of little utility for interpretation. Thus CAT
and CuZnSOD examined in this study will be of little use
in the diagnosis of early or latent of diabetes. The results
of our studies were similar to results of Covas et al. [30].
This author reported that II for CuZnSOD and glutathione
peroxidase in blood was 0.45, suggesting that it has little
value as a diagnostic or screening tool. In our study, the II
for MDA was found to be >1.4 according to the discrimin-
ant values proposed by Fraser and Harris [20]; hence this
analyte may be useful for diagnosis and screening of T2DM
or DN. At this point, it would be worthwhile to check for
statistically significant differences according to sex, to see
whether a separation of reference values is indicated.
The RCV is an important clinical tool for the assessment
of changes in patients being monitored in pathological sit-
uations [25]. The present study showed that II < 0.6 indi-
cates the range at which RCVs for CAT and CuZnSOD
may be substituted for the reference interval. However,
RCVs for CAT and CuZnSOD were higher in patient
groups than healthy individuals. Hence, RCVs for CAT
and CuZnSOD may be clinically useful in T2DM and DN.
Therefore, the RCV for predicting crises in urine of both
diabetic groups represents an optimization of laboratory
reporting and may be a valuable tool for clinical decision
making. Fraser et al. [31] reported that RCV can be used
to set objective criteria for use in delta-checking quality
control techniques. Rather than spending considerable re-
sources in defining reference intervals, laboratories are
urged to apply well-established methodology to calculate
RCV and to use these in everyday practice, providing con-
siderable advantage in the monitoring of changes in serial
results from individuals.
The current European consensus is that analytical
quality specifications are best based on components of
biological variation [26]. We have, as far as we are aware,
documented the biological variation of oxidative stress
in urine for the first time. In our study, a desirable ana-
lytical CV of 0.5 times CVI is usually considered because
this assay imprecision adds only a 23% to the data vari-
ability [32]. In the present study, the imprecision of our
Kurutas et al. Biological Procedures Online  (2015) 17:3 Page 7 of 7laboratory methods for measuring oxidative stress bio-
markers in urine was found less than the desirable impre-
cision goals. Analytical quality specifications were derived
from biological variation data, and imprecision goals can
be reasonably achieved with current methods. Therefore,
it is hoped that these biological variation data may serve
to apply this approach in the analysis of urinary oxidative
stress biomarkers.
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